Novel Phenolic Inhibitors of Small/Intermediate-Conductance Ca2+-Activated K+ Channels, KCa3.1 and KCa2.3

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Oliván Viguera, Aida ^a,b   Valero, Marta Sofía ^c   Murillo, María Divina ^d   Wulff, Heike ^e   García Otín, Ángel Luis ^a,f   Arbonés Mainar, José Miguel ^a,f   Köhler, Ralf ^a,b,g  

^a INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD   (Spain)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c UNIVERSIDAD SAN JORGE   (Spain)

^d UNIVERSIDAD DE ZARAGOZA   (Spain)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^g FUNDACIÓN ARAID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1 [(2 CHLOROPHENYL)DIPHENYLMETHYL] 1H PYRAZOLE; 1,2,3,4,6 PENTAGALLOYL GLUCOSE; [3,5 BIS[(3 CHLORO 4 HYDROXY BENZOYL)OXYMETHYL]PHENYL]METHYL 3 CHLORO 4 HYDROXYBENZOATE; [3,5 BIS[(3 FLUORO 4 HYDROXY BENZOYL)OXYMETHYL]PHENYL]METHYL 3 FLUORO 4 HYDROXYBENZOATE; [3,5 BIS[(4 HYDROXY 3 METHOXY BENZOYL)OXYMETHYL]PHENYL]METHYL 4 HYDROXY 3 METHOXYBENZOATE; ACETYLSALICYLIC ACID; BENZOIC ACID DERIVATIVE; CAFFEIC ACID; CAFFEIC ACID PHENETHYL ESTER; FERULIC ACID; FLUFENAMIC ACID; GALLIC ACID; HYDROXYTYROSOL; INTERMEDIATE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; INTERMEDIATE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL KCA1.1; INTERMEDIATE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL KCA2.3; INTERMEDIATE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL KCA3.1; MEFENAMIC ACID; MESALAZINE; MODAFINIL; NAPHTHO[1,2 D][1,3]THIAZOL 2 AMINE; NIFLUMIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PIRFENIDONE; POLYPHENOL; RESVERATROL; SEROTONIN; SKA 31; UNCLASSIFIED DRUG; VANILLIC ACID; VOLTAGE GATED POTASSIUM CHANNEL;

ANIMAL CELL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING SITE; CELL STRAIN 3T3; CELL STRAIN HEK293; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY CONSTRICTION; CYTOTOXICITY; DRUG POTENCY; DRUG SELECTIVITY; EMBRYO; EX VIVO STUDY; HUMAN; MEMBRANE ELECTROPHYSIOLOGY; MOLECULAR DYNAMICS; MOUSE; MYOGRAPHY; NONHUMAN; PATCH CLAMP; PHARMACOLOGICAL BLOCKING; PROTEIN PROTEIN INTERACTION; SWINE; VASODILATATION;

3T3 CELLS; ANIMALS; BIOLOGICAL AGENTS; CELL PROLIFERATION; CORONARY VESSELS; ENDOTHELIAL CELLS; FIBROBLASTS; HEK293 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; ION CHANNEL GATING; MEMBRANE POTENTIALS; MICE; PHENOLS; POTASSIUM CHANNEL BLOCKERS; SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; SWINE;

EID: 84875027831     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058614     Document Type: Article

References (47)

1. Wei AD, Gutman GA, Aldrich R, Chandy KG, Grissmer S, et al. (2005) International Union of Pharmacology. LII. Nomenclature and molecular relationships of calcium-activated potassium channels. Pharmacol Rev 57: 463-472.
2. Ishii TM, Silvia C, Hirschberg B, Bond CT, Adelman JP, et al. (1997) A human intermediate conductance calcium-activated potassium channel. Proc Natl Acad Sci U S A 94: 11651-11656.
3. Vandorpe DH, Shmukler BE, Jiang L, Lim B, Maylie J, et al. (1998) cDNA cloning and functional characterization of the mouse Ca2+-gated K+ channel, mIK1. Roles in regulatory volume decrease and erythroid differentiation. J Biol Chem 273: 21542-21553.
4. Grgic I, Kaistha BP, Paschen S, Kaistha A, Busch C, et al. (2009) Disruption of the Gardos channel (KCa3.1) in mice causes subtle erythrocyte macrocytosis and progressive splenomegaly. Pflugers Arch 458: 291-302.
5. Wulff H, Miller MJ, Hansel W, Grissmer S, Cahalan MD, et al. (2000) Design of a potent and selective inhibitor of the intermediate-conductance Ca2+-activated K+ channel, IKCa1: a potential immunosuppressant. Proc Natl Acad Sci U S A 97: 8151-8156.
6. Devor DC, Singh AK, Frizzell RA, Bridges RJ, (1996) Modulation of Cl- secretion by benzimidazolones. I. Direct activation of a Ca(2+)-dependent K+ channel. Am J Physiol 271: L775-784.
7. Kroigaard C, Dalsgaard T, Nielsen G, Laursen BE, Pilegaard H, et al. (2012) Activation of endothelial and epithelial K(Ca) 2.3 calcium-activated potassium channels by NS309 relaxes human small pulmonary arteries and bronchioles. Br J Pharmacol 167: 37-47.
8. Köhler R, Degenhardt C, Kuhn M, Runkel N, Paul M, et al. (2000) Expression and function of endothelial Ca2+-activated K+ channels in human mesenteric artery: A single-cell reverse transcriptase-polymerase chain reaction and electrophysiological study in situ. Circ Res 87: 496-503.
9. Edwards G, Dora KA, Gardener MJ, Garland CJ, Weston AH, (1998) K+ is an endothelium-derived hyperpolarizing factor in rat arteries. Nature 396: 269-272.
10. Grgic I, Eichler I, Heinau P, Si H, Brakemeier S, et al. (2005) Selective blockade of the intermediate-conductance Ca2+-activated K+ channel suppresses proliferation of microvascular and macrovascular endothelial cells and angiogenesis in vivo. Arterioscler Thromb Vasc Biol 25: 704-709.
11. Köhler R, Wulff H, Eichler I, Kneifel M, Neumann D, et al. (2003) Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis. Circulation 108: 1119-1125.
12. Neylon CB, Lang RJ, Fu Y, Bobik A, Reinhart PH, (1999) Molecular cloning and characterization of the intermediate-conductance Ca(2+)-activated K(+) channel in vascular smooth muscle: relationship between K(Ca) channel diversity and smooth muscle cell function. Circ Res 85: e33-43.
13. Pena TL, Rane SG, (1999) The fibroblast intermediate conductance K(Ca) channel, FIK, as a prototype for the cell growth regulatory function of the IK channel family. J Membr Biol 172: 249-257.
14. Grgic I, Kiss E, Kaistha BP, Busch C, Kloss M, et al. (2009) Renal fibrosis is attenuated by targeted disruption of KCa3.1 potassium channels. Proc Natl Acad Sci U S A 106: 14518-14523.
15. Arcangeli A, Crociani O, Lastraioli E, Masi A, Pillozzi S, et al. (2009) Targeting ion channels in cancer: a novel frontier in antineoplastic therapy. Curr Med Chem 16: 66-93.
16. Abdullaev IF, Rudkouskaya A, Mongin AA, Kuo YH, (2010) Calcium-activated potassium channels BK and IK1 are functionally expressed in human gliomas but do not regulate cell proliferation. PLoS One 5: e12304.
17. Lambertsen KL, Gramsbergen JB, Sivasaravanaparan M, Ditzel N, Sevelsted-Moller LM, et al. (2012) Genetic KCa3.1-Deficiency Produces Locomotor Hyperactivity and Alterations in Cerebral Monoamine Levels. PLoS One 7: e47744.
18. Wulff H, Zhorov BS, (2008) K+ channel modulators for the treatment of neurological disorders and autoimmune diseases. Chem Rev 108: 1744-1773.
19. Toyama K, Wulff H, Chandy KG, Azam P, Raman G, et al. (2008) The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans. J Clin Invest 118: 3025-3037.
20. Tharp DL, Wamhoff BR, Wulff H, Raman G, Cheong A, et al. (2008) Local delivery of the KCa3.1 blocker, TRAM-34, prevents acute angioplasty-induced coronary smooth muscle phenotypic modulation and limits stenosis. Arterioscler Thromb Vasc Biol 28: 1084-1089.
21. Köhler R, Kaistha BP, Wulff H, (2010) Vascular KCa-channels as therapeutic targets in hypertension and restenosis disease. Expert Opin Ther Targets 14: 143-155.
22. Lamoral-Theys D, Pottier L, Kerff F, Dufrasne F, Proutiere F, et al. (2010) Simple di- and trivanillates exhibit cytostatic properties toward cancer cells resistant to pro-apoptotic stimuli. Bioorg Med Chem 18: 3823-3833.
23. Lamoral-Theys D, Wauthoz N, Heffeter P, Mathieu V, Jungwirth U, et al. (2012) Trivanillic polyphenols with anticancer cytostatic effects through the targeting of multiple kinases and intracellular Ca2+ release. J Cell Mol Med 16: 1421-1434.
24. Cao YJ, Houamed KM, (1999) Activation of recombinant human SK4 channels by metal cations. FEBS Lett 446: 137-141.
25. Werkman TR, Kawamura T, Yokoyama S, Higashida H, Rogawski MA, (1992) Charybdotoxin, dendrotoxin and mast cell degranulating peptide block the voltage-activated K+ current of fibroblast cells stably transfected with NGK1 (Kv1.2) K+ channel complementary DNA. Neuroscience 50: 935-946.
26. Grissmer S, Nguyen AN, Aiyar J, Hanson DC, Mather RJ, et al. (1994) Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol Pharmacol 45: 1227-1234.
27. Sankaranarayanan A, Raman G, Busch C, Schultz T, Zimin PI, et al. (2009) Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure. Mol Pharmacol 75: 281-295.
28. Raspotnig G, Fauler G, Jantscher A, Windischhofer W, Schachl K, et al. (1999) Colorimetric determination of cell numbers by Janus green staining. Anal Biochem 275: 74-83.
29. Alda JO, Valero MS, Pereboom D, Gros P, Garay RP, (2009) Endothelium-independent vasorelaxation by the selective alpha estrogen receptor agonist propyl pyrazole triol in rat aortic smooth muscle. J Pharm Pharmacol 61: 641-646.
30. Valero MS, Pereboom D, Barcelo-Batllory S, Brines L, Garay RP, et al. (2011) Protein kinase A signalling is involved in the relaxant responses to the selective beta-oestrogen receptor agonist diarylpropionitrile in rat aortic smooth muscle in vitro. J Pharm Pharmacol 63: 222-229.
31. Zhang XH, Zhang YY, Sun HY, Jin MW, Li GR, (2012) Functional ion channels and cell proliferation in 3T3-L1 preadipocytes. J Cell Physiol 227: 1972-1979.
32. Ledoux J, Bonev AD, Nelson MT, (2008) Ca2+-activated K+ channels in murine endothelial cells: block by intracellular calcium and magnesium. J Gen Physiol 131: 125-135.
33. Choi S, Kim MY, Joo KY, Park S, Kim JA, et al. (2012) Modafinil inhibits K(Ca)3.1 currents and muscle contraction via a cAMP-dependent mechanism. Pharmacol Res 66: 51-59.
34. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, et al. (2011) Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377: 1760-1769.
35. Srivastava S, Zhdanova O, Di L, Li Z, Albaqumi M, et al. (2008) Protein histidine phosphatase 1 negatively regulates CD4 T cells by inhibiting the K+ channel KCa3.1. Proc Natl Acad Sci U S A 105: 14442-14446.
36. Srivastava S, Di L, Zhdanova O, Li Z, Vardhana S, et al. (2009) The class II phosphatidylinositol 3 kinase C2beta is required for the activation of the K+ channel KCa3.1 and CD4 T-cells. Mol Biol Cell 20: 3783-3791.
37. Gerlach AC, Syme CA, Giltinan L, Adelman JP, Devors DC, (2001) ATP-dependent activation of the intermediate conductance, Ca2+-activated K+ channel, hIK1, is conferred by a C-terminal domain. J Biol Chem 276: 10963-10970.
38. Rosa JC, Galanakis D, Ganellin CR, Dunn PM, Jenkinson DH, (1998) Bis-quinolinium cyclophanes: 6,10-diaza-3(1,3),8(1,4)-dibenzena-1,5(1,4)- diquinolinacyclodecaphane (UCL 1684), the first nanomolar, non-peptidic blocker of the apamin-sensitive Ca2+-activated K+ channel. J Med Chem 41: 2-5.
39. Ottolia M, Toro L, (1994) Potentiation of large conductance KCa channels by niflumic, flufenamic, and mefenamic acids. Biophys J 67: 2272-2279.
40. Malykhina AP, Shoeb F, Akbarali HI, (2002) Fenamate-induced enhancement of heterologously expressed HERG currents in Xenopus oocytes. Eur J Pharmacol 452: 269-277.
41. Huang MT, Smart RC, Wong CQ, Conney AH, (1988) Inhibitory effect of curcumin, chlorogenic acid, caffeic acid, and ferulic acid on tumor promotion in mouse skin by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res 48: 5941-5946.
42. Phipps DJ, Branch DR, Schlichter LC, (1996) Chloride-channel block inhibits T lymphocyte activation and signalling. Cell Signal 8: 141-149.
43. Strobaek D, Brown DT, Jenkins DP, Chen YJ, Coleman N, et al. (2012) NS6180, a new K(Ca) 3.1 channel inhibitor prevents T-cell activation and inflammation in a rat model of inflammatory bowel disease. Br J Pharmacol.
44. Jenkins DP, Strobaek D, Hougaard C, Jensen ML, Hummel R, et al. (2011) Negative gating modulation by (R)-N-(benzimidazol-2-yl)-1,2,3,4-tetrahydro-1-naphthylamine (NS8593) depends on residues in the inner pore vestibule: pharmacological evidence of deep-pore gating of K(Ca)2 channels. Mol Pharmacol 79: 899-909.
45. Wulff H, Gutman GA, Cahalan MD, Chandy KG, (2001) Delineation of the clotrimazole/TRAM-34 binding site on the intermediate conductance calcium-activated potassium channel, IKCa1. J Biol Chem 276: 32040-32045.
46. Zhang M, Pascal JM, Schumann M, Armen RS, Zhang JF, (2012) Identification of the functional binding pocket for compounds targeting small-conductance Ca(2)(+)-activated potassium channels. Nat Commun 3: 1021.
47. Brähler S, Kaistha A, Schmidt VJ, Wolfle SE, Busch C, et al. (2009) Genetic deficit of SK3 and IK1 channels disrupts the endothelium-derived hyperpolarizing factor vasodilator pathway and causes hypertension. Circulation 119: 2323-2332.